EP Patent

EP3930702A1 — Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state

Assigned to Flamel Ireland Ltd · Expires 2022-01-05 · 4y expired

What this patent protects

Oral pharmaceutical compositions of sodium oxybate having improved pharmacokinetic properties when administered less than two hours after eating are provided, and therapeutic uses thereof.

USPTO Abstract

Oral pharmaceutical compositions of sodium oxybate having improved pharmacokinetic properties when administered less than two hours after eating are provided, and therapeutic uses thereof.

Drugs covered by this patent

Patent Metadata

Patent number
EP3930702A1
Jurisdiction
EP
Classification
—
Expires
2022-01-05
Drug substance claim
No
Drug product claim
No
Assignee
Flamel Ireland Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.